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Loss of Proapoptotic Bcl-2-Related Multidomain
Proteins in Primary Melanomas Is Associated with
Poor Prognosis
Lothar F. Fecker1, Christoph C. Geilen1, Georgi Tchernev1, Uwe Trefzer1, Chalid Assaf1,
Bachtier M. Kurbanov1, Constanze Schwarz1, Peter T. Daniel2 and Ju¨rgen Eberle1
Prognosis of primary melanoma is presently based on morphological parameters, mainly tumor thickness.
However, more reliable prognostic markers are needed that allow a better stratification of patients, especially
with regard to therapeutic options. Here, a retrospective study was performed on patients with primary
superficial-spreading melanoma (SSM, n¼ 44) or nodular melanoma (n¼ 16) of 1.5–4 mm thickness. Thirty
patients had survived the follow-up of 10 years, whereas the other 30 patients developed metastases. Tumor
sections were analyzed by immunohistochemistry for the expression of regulators of the cell cycle (p21;
retinoblastoma protein (pRb)), of the intrinsic or extrinsic proapoptotic pathways (p53; murine double minute
gene 2 protein; tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-R1/DR4; TRAIL-R2/DR5) and of
Bcl-2-related proteins (Bcl-2, Mcl-1, Bax, Bak, Bok), which regulate the common mitochondrial apoptotic
pathway. In SSM, decrease of Bax and Bak was significantly correlated with a poor prognosis: high Bax was
associated with 10-year survival rates of 68%, whereas low Bax resulted in only 26% survival, and high Bak was
associated with 10-year survival rates of 62%, whereas low Bak resulted in only 10% survival. Regulators of
apoptosis may therefore candidate for independent prognostic markers for primary melanomas. The study
underlines the particular role of the mitochondrial apoptosis pathway and of proapoptotic Bcl-2-related
proteins for melanoma progression.
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INTRODUCTION
Malignant melanoma of the skin results in mortality rates
higher than for all other skin cancers together (Garbe and
Blum, 2001). A strong issue of melanoma malignancy is the
pronounced resistance to conventional chemotherapies,
which may result from diverse defects in signaling cascades
leading to programmed cell death/apoptosis (Soengas and
Lowe, 2003). Melanoma prognosis is based mainly on
morphological parameters such as tumor thickness and tumor
spread, leaving a 10-year survival expectancy of less than 3%
for patients with distant metastases. Melanomas of 1.5–4 mm
have a metastatic potential of about 30% (Eigentler et al.,
2004), thus challenging for new prognostic markers, which
may allow early assessment of the disease, especially with
regard to therapeutic options.
Apoptosis is a genetically regulated death program with
high impact on growth of neoplasms. A large number of
apoptosis-regulating factors have been described, which may
also be of prognostic value. Two main death pathways
(extrinsic and intrinsic) originate from death receptor
stimulation and from intracellular damage signals, respec-
tively. The extrinsic pathway is initiated by binding of death
ligands, such as tumor necrosis factor-a, CD95L/Fas ligand or
tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL), to their respective death receptors, whereas p53 is
the master regulator of the intrinsic pathway and triggers cell
cycle arrest as well as apoptosis upon cellular stress and DNA
damage. Among its characteristic targets are cell cycle
inhibitors such as p21CIP1/WAF1 and proapoptotic Bcl-2-
related proteins such as Bax (Vousden, 2002). P53 itself is
negatively controlled by the ubiquitin ligase MDM2.
Intrinsic and extrinsic proapoptotic pathways may meet in
the mitochondrial amplification loop, which therefore
becomes of particular interest also for anticancer therapies
(Cory and Adams, 2002). The characteristic release of
proapoptotic mitochondrial factors, such as cytochrome c,
is controlled by pro- and antiapoptotic Bcl-2-related proteins,
which are characterized by the presence of one to four Bcl-2
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homology domains (BH1–BH4). Antiapoptotic Bcl-2 proteins
such as Bcl-2 or Mcl-1 share all four domains, whereas
proapoptotic proteins lack one or several of the BH domains.
Proapoptotic Bcl-2 proteins further subdivide in BH3-only
proteins such as Bad, Bid, Nbk/Bik, and multidomain proteins
such as Bax, Bak, and Bok (Daniel et al., 2001).
In previous work, we have shown that apoptosis resistance
of melanoma cells can be overcome by triggering the
expression of proapoptotic proteins (Eberle et al., 2003;
Hossini et al., 2003; Fecker et al., 2005; Oppermann et al.,
2005). In the present retrospective study, we investigated the
expression of anti- and proapoptotic mediators of apoptosis
pathways in melanoma. As the main result, loss of
proapoptotic Bcl-2-related multidomain proteins Bax and
Bak in primary melanoma turned out as predictors for an
unfavorable prognosis.
RESULTS
Varying expression of apoptosis and cell cycle regulators in
primary melanomas
For a first screening, a retrospective study was performed with
sections of 24 superficial-spreading melanomas (SSM,
1.5–4 mm tumor thickness). Twelve patients had survived
the 10-year follow-up period without tumor progression,
whereas the other 12 patients developed metastases and died
within the 10-year period (median survival: 31 months). Both
subgroups were characterized by comparable median values
for age and tumor thickness. By immunohistology, expression
of regulators of the cell cycle (p21; retinoblastoma protein
(pRb)), of the intrinsic and extrinsic proapoptotic pathway
(p53; murine double minute gene 2 protein (MDM2); TRAIL-
R1/DR4 and TRAIL-R2/DR5) and of the proapoptotic mito-
chondrial amplification loop (Bcl-2, Mcl-1, Bax, Bak, Bok)
were investigated.
Variable numbers of positive and negative tumors (cutoff
for negative tumors: 2%) were seen for each marker (Figure 1).
Only 29% of SSM stained positive for p53, the key regulator
of the intrinsic apoptosis pathway, whereas 83% were
positive for its negative regulator MDM2. Also, the median
number of stained cells in positive tumors was lower for p53
(20%) than for MDM2 (50%). Both antigens were restricted to
nuclei. Of the death receptor family, both agonistic TRAIL
receptors, TRAIL-R1/DR4 and TRAIL-R2/DR5, were ex-
pressed in over 90% of the SSM investigated. Also, the
median number of stained cells was high: 50 and 70% for
DR4 and DR5, respectively. Two characteristic negative
regulators of the cell cycle, p21 and pRb, showed nuclear
staining in about 60% of the tumors; however, the range of
positivity was low for both markers with at maximum 30%
positive cells in individual tumors resulting in median values
of 5 and 10%, respectively. Of the large Bcl-2 family, critical
regulators of the mitochondrial pathway, antiapoptotic Bcl-2
and Mcl-1 as well as proapoptotic Bax, Bak, and Bok, were
investigated. Bcl-2-related proteins were found in 75–91% of
the tumors. The median number of stained cells in positive
tumors ranged between 47 and 65% (Table 2).
For the estimation of the prognostic value of the respective
markers, their expression was compared in SSM patients with
and without tumor progression. As detailed by box-plot
analysis (Figure 2), no significant change was seen for
markers p21 (P40.1), pRB (P40.7), DR4 (P40.6), DR5
(P40.4), p53 (P40.4), and MDM2 (P40.2; Mann–Whitney
U-test).
Loss of Bax and Bak in SSM with unfavorable prognosis
According to the first screening with 24 SSM patients, the
strongest differences were seen for the proapoptotic Bcl-2-
related proteins Bax and Bak. Therefore, immunohistological
stainings for Bcl-2-related proteins Bax, Bak, Bok, Mcl-1, and
Bcl-2 were performed for a second series of SSM patients (10
with tumor progression and 10 without). Furthermore, Bax,
Bak, Bok, and Mcl-1 were investigated in a series of 16
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Figure 1. Variant expression of apoptosis and cell cycle markers in primary melanomas. Expression of indicated proteins was investigated by
immunohistochemistry in a series of 24 SSM (1.5–4 mm). For each antigen, a positive and a negative tumor is shown. The magnification scale is indicated below
the figure.
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patients with nodular melanoma. The respective patient
collectives were characterized by highly similar median
values for age and tumor thickness (Table 1).
Immunohistological evaluation of 44 SSM patients re-
vealed statistically significant downregulation of Bax
(Po0.02) and of Bak (Po0.05; Mann–Whitney U-test) in
patients with tumor progression, whereas Bok, Bcl-2, and
Mcl-1 did not reveal significant changes (Figure 3a, Table 2).
Double-negative tumors for Bax and Bak were exclusively
found in patients with tumor progression (8/22, 36%).
Double-positive tumors for Bax and Bak were found in 7/22
(32%) in patients with tumor progression as compared to 16/
22 (73%) in patients without tumor progression. In contrast,
no downregulation of Bax was seen in nodular melanomas,
and the tendency of Bak downregulation was weaker than
seen in SSM (data not shown).
For further comparison, 12 melanoma lymph node
metastases were investigated for the expression of Bcl-2-
related proteins. Only S100-positive cells were evaluated. In
these samples, strong downregulation of both pro- and
antiapoptotic Bcl-2 proteins was found (Bax, 75%; Bak,
83%; Bok, 75%; Bcl-2, 58%; Mcl-1, 67%; cutoff level: 20%
positive tumor cells). These findings may be indicative for a
special situation of apoptosis regulators in melanoma
metastases independent from their pro- or antiapoptotic
function, possibly related to the different growth situation.
With respect to patient survival, Bax and Bak turned out as
highly selective. For analysis, patients were subdivided for
each marker in two groups corresponding to high or low Bax
or Bak expression (cutoff level: 20% positive tumor cells).
Only one of 10 SSM patients with low Bak survived 10 years
(10%), in contrast to 21 of 34 survivors with high Bak (62%).
Similarly, of 19 SSM patients with low Bax, only five survived
10 years (26%), in contrast to 17 of 25 survivors with high
Bax (68%). Kaplan–Meier analysis clearly demonstrated the
significant correlation between low Bax or Bak expression
and reduced SSM patient survival (log-rank test: Bax,
Po0.01; Bak, Po0.005; Figure 3b).
DISCUSSION
Prognosis of primary melanoma has been shown to be
associated with tumor thickness, ulceration, and lymphan-
giogenesis (Clark Jr et al., 1969; Breslow, 1970; Dadras et al.,
2005). For identifying additional prognostic markers, several
immunohistological studies had applied a comparison of
primary melanoma and metastases. However, the different
growth situation may by itself result in changes of gene
expression, which may be even independent from the grade
of malignancy, as we found here downregulation of both pro-
and antiapoptotic Bcl-2 proteins in lymph node metastases.
Other complications may arise from variant gene expression
in melanoma subtypes such as nodular melanoma or SSM.
The present retrospective study was performed with a tightly
defined collective of melanoma patients (SSM, 1.5–4 mm),
and patients with good versus bad outcome with respect to
10-year survival were compared.
Several previous studies have focused on the expression of
characteristic cell cycle regulators; however, deviating data
have been published with regard to their prognostic value
(Straume et al., 2000; Georgieva et al., 2001; Korabiowska
et al., 2001; Bachmann et al., 2004). Our analysis of p21 and
pRb expression revealed overall weak expression levels of
these proteins in primary melanomas, but no significant
change with respect to prognosis.
Apoptosis deficiency represents a characteristic feature of
malignancies and may also be related to chemotherapy
resistance. Whereas the intrinsic pathway is controlled by
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Figure 2. Variant expression of different apoptosis and cell cycle marker
proteins. Box-plot diagrams indicate the median percentages and the
variation of positive tumor cells in primary melanomas for regulatory proteins
of the intrinsic apoptosis pathway (p53, MDM2) of the extrinsic apoptotis
pathway (DR4, DR5) and of cell cycle regulators (p21, pRb), as determined by
immunohistochemistry. Twelve SSM patients with tumor progression (P) were
compared to 12 patients without tumor progression (w/o).
Table 1. Clinical data of melanoma patients
Type1 n2 Progression Age (years)3 Sex (females/males) Tumor thickness (mm)3 Survival (months)3
SSM 22 No 55 (56713) 13/9 2.4 (2.570.7) 120
SSM 22 Yes 57 (57715) 11/11 2.3 (2.470.6) 36 (38723)
NM 8 No 61 (59710) 6/2 2.6 (2.770.7) 120
NM 8 Yes 65 (62714) 3/5 2.8 (2.970.8) 34 (31718)
1Histological type (SSM: superficial-spreading melanoma; NM: nodular melanoma).
2Number of patients investigated.
3Median values for age and tumor thickness at the time of surgery and patient survival after excision of the primary tumor; mean values and SED are given
within parenthesis.
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p53 and its negative regulator MDM2, the extrinsic apoptotic
pathway is based on the activation of death receptors (Sprick
and Walczak, 2004). In the present study, neither significant
changes in expression of p53 and MDM2 nor of the death
receptors TRAIL-R1/DR4 or TRAIL-R2/DR5 were obvious,
possibly indicating that the block at one or the other branch
of the apoptosis pathways may be less contributive for
melanoma progression.
For many tumors, extrinsic and intrinsic apoptosis path-
ways merge in the mitochondrial amplification loop, which
therefore becomes of particular interest for anticancer
approaches (Cory and Adams, 2002). Also for melanoma
cells, we had demonstrated a high impact of the mitochon-
drial pathway for apoptosis control (Raisova et al., 2001;
Hossini et al., 2003; Oppermann et al., 2005). Pro- and
antiapoptotic Bcl-2-related proteins appear as master regula-
tors of this pathway. Antiapoptotic Bcl-2 or Mcl-1 are integral
components of the outer mitochondrial membrane and they
prevent mitochondrial damage (Daniel et al., 2001). Their
high expression has been attributed to chemoresistance in
melanoma (Tang et al., 1998; Jansen et al., 2000), and the
ratio of Bax to Bcl-2 appeared as decisive for melanoma cell
susceptibility to apoptotic signals (Raisova et al., 2001).
Accordingly, antisense strategies targeting Bcl-2 or Mcl-1 are
underway (Jansen et al., 2000; Thallinger et al., 2003). In the
present study, the majority of primary melanomas revealed
Bcl-2 as well as Mcl-1 expression, but no relation to
prognosis.
Central players of the mitochondrial apoptosis pathway
are the multidomain, proapoptotic Bcl-2-related proteins
Bax, Bak, and Bok, which are assumed as antagonists for
antiapoptotic Bcl-2 proteins (Daniel et al., 2003). Whereas
Bax is found in the cytosol before induction, Bak and Bok
already reside in the mitochondrial membrane and in the
endoplasmic reticulum (Daniel et al., 2001). Loss of Bax
expression as a negative prognostic marker has been reported
for breast, ovarian, pancreatic, and esophageal cancer
(Krajewski et al., 1995; Friess et al., 1998; Tai et al., 1998;
Guner et al., 2003; Daniel et al., 2003). In the present study,
we found loss of Bax to be associated with tumor progression
in SSM, and 10-year survival rates were dramatically
decreased. In previous work, we demonstrated the critical
role of the Bax/Bcl-2 ratio for melanoma cell susceptibility to
apoptotic stimuli (Raisova et al., 2001). Thus, loss of Bax in
melanomas may reflect reduced susceptibility to immune
response and chemotherapy.
No immunohistochemical data on Bak or Bok were
available for melanoma, but cisplatin-induced apoptosis in
Table 2. Localization and expression of antigens in
SSM
Antigen n1 Staining2
Positive
tumors3 (%)
Positive
cells4 (%)
Bax 44 Cyto 75 47
Bak 44 Cyto 86 65
Bok 44 Cyto 91 53
Bcl-2 44 Cyto 82 60
Mcl-1 37 Cyto 78 50
p53 24 Nucl 29 20
MDM2 23 Nucl 83 50
DR4 22 Cyto 91 50
DR5 20 Cyto 95 70
p21 24 Nucl 58 5
pRb 24 Nucl 67 10
1Number of superficial-spreading melanomas (SSM) investigated by
immunohistology.
2Cyto, cytoplasmic staining pattern; nucl, nuclear staining pattern.
3Percentage of melanoma lesions that stained positive for the respective
antigen (cutoff level for positive tumors: 2% stained cells).
4Median percentage of stained cells in the positive tumors.
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Figure 3. Weak expression of Bax and Bak correlates with reduced survival.
(a) Box-plot diagrams indicate expression levels of pro- and antiapoptotic
proteins of the Bcl-2 family (Bax, Bak, Bok, Bcl-2, and Mcl-1) in a series of 44
SSM from patients with tumor progression (P; n¼ 22) and patients without
tumor progression (w/o; n¼ 22). (b) Reduced survival of SSM patients with
low expression of Bax and Bak is shown by Kaplan–Meier analyses. For
comparison, survival graphs for Bcl-2 and Mcl-1 are also given. High and low
expression was defined as more than 20% positive tumor cells, respectively,
as up to 20% positive cells.
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melanoma cells has been shown to require Bak (Mandic
et al., 2001). The proapoptotic activity of Bok has been
demonstrated in neuronal cells and cervical carcinoma cells
(Hsu et al., 1997; Yakovlev et al., 2004). The present study
revealed expression of Bak and of Bok in the majority of
primary melanomas. Downregulation of Bak was associated
with poorer prognosis in SSM, whereas Bok did not reveal
any significant changes.
In conclusion, our data underline the critical role of the
mitochondrial pathway for apoptosis signaling in melanoma.
At an early stage of melanoma development, loss of
expression of proapoptotic Bcl-2-related proteins may block
apoptotic signals, as derived from the immune system or from
the intrinsic apoptotic pathway. This loss appears to be
characteristic for tumor progression and may thus serve as a
negative prognostic marker for primary melanoma.
MATERIALS AND METHODS
Melanoma patients and immunohistology
Sections of primary melanomas resulted from patients with SSM
or nodular melanoma (1.5–4 mm tumor thickness). Clinical
follow-up for 10 years was available for all surviving patients.
Respective patients subgroups were characterized by highly
comparable mean age and tumor thickness (Table 1). Sections of
12 melanoma lymph node metastases resulted from a separate
patient collective.
Sections of 4–6mm from formalin-fixed and paraffin-embedded
melanoma samples were attached to SuperFrost plus slides (Roth,
Karlsruhe, Germany) at 601C for 4 hours. After xylol treatment, they
were re-hydrated and equilibrated in Tris-buffered saline, pH 7.5,
followed by pressure cooker boiling for 3 minutes in sodium citrate
buffer (10 mM, pH 6) and equilibration in Tris-buffered saline.
Subsequent incubation steps were performed in humidity chambers
at room temperature, and all incubation steps were followed by
washing slides thoroughly in Tris-buffered saline, 0.05% Tween.
Sections were treated first at room temperature for 30 minutes with
protein blocking solution (DakoCytomation, Hamburg, Germany)
and were then incubated with the respective primary mouse
monoclonal or rabbit polyclonal antibody for 1 hour (Bok antibody
for 14 hours). For mouse monoclonal antibodies, slides were then
incubated (1) for 30 minutes with rabbit anti-mouse antibody
(DakoCytomation, Z0259) diluted 1:20 in growth medium supplied
with human serum (HUSE) (87.5% RPMI medium, 10% heat-
inactivated fetal calf serum, 12.5% human serum), and (2) for
30 minutes with the alkaline phosphatase anti-alkaline phosphatase
(APAAP) complex (DakoCytomation, D0651) diluted 1:50 in RPMI
(10% fetal calf serum). Both incubations were repeated once for
10 minutes. For the detection of rabbit polyclonal antibodies, slides
were incubated (1) for 30 minutes with mouse anti-rabbit antibodies
(DakoCytomation, M0737) diluted 1:200 in HUSE; (2) for 30 minutes
with rabbit anti-mouse antibody solution diluted 1:20 in HUSE, and
(3) for 30 minutes with the APAAP complex diluted as described
above.
Slides were then stained for 15 minutes with the fuchsine
substrate–chromogen system (DakoCytomation, K0624). Counter-
staining was performed with Mayer’s hematoxylin (Merck, Darm-
stadt, Germany). Optimal dilutions were established for all
antibodies. Negative controls were always run in parallel: mouse
IgG1 control antibody (DakoCytomation, X0931; for monoclonal
antibodies), or the primary antibody was omitted (polyclonal
antibodies).
The following mouse monoclonal and rabbit polyclonal anti-
bodies and antibody dilutions have been applied: Bax (YTH-2D2,
Biozol, Eching, Germany, 1:800); Bak (polyclonal, DakoCytoma-
tion, 1:175); Bok (polyclonal, New England Biolabs, Frankfurt a. M.,
Germany, 1:50); Bcl-2 (clone 124, DakoCytomation, 1:100); Mcl-1
(RC13, Acris, Hiddenhausen, Germany, 1:50 or polyclonal,
AHP472, Serotec, Du¨sseldorf, Germany, 1:1500); p53 (DO-7,
DakoCytomation, 1:75); MDM2 (SMP14, Dianova, Hamburg,
Germany, 1:100); DR4 (polyclonal, Acris, 1:150); DR5 (polyclonal,
Acris, 1:100), p21 (6B6, BD Pharmingen, Heidelberg, Germany,
1:400); pRb (G3-245, BD Pharmingen, 1:750); and S100 (polyclonal,
DakoCytomation, 1:500).
Evaluation and statistics
For each slide, staining of the complete tumor section was evaluated
by microscopy without knowing the patients’ clinical details. For
each section, the percentage of melanoma cells with strong,
medium, weak, or absent staining was determined. Melanoma cells
in primary tumors and metastases were confirmed by S100 staining.
Only strong and medium cell staining was considered as positive.
Statistical significance was calculated by Mann–Whitney U-test.
Kaplan–Meier survival analysis was performed for patients with low
and high expression of markers (cutoff value: 20% positive cells).
Significance of differences in survival was determined by means of
the log-rank test.
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